Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Adherex Technologies reported Q2 EPS of $0.05, beating analyst expectations of $0.02 by $0.03. PEDMARK sales rose 78% year over year to $17.1 million, while adjusted EBITDA improved to $2.8 million from a $1.2 million loss.
• Commercial momentum strengthened, with double-digit sequential demand growth, record patient enrollments and infusions, and July setting multiple company records. The company is also advancing clinical studies and exploring potential partnerships in Japan and the Asia-Pacific region.
• Higher commercial and marketing investments lifted operating expenses to about $13.6 million, and management expects cash to decline in Q3 before potentially generating positive cash flow in Q4. Analysts maintain a “Moderate Buy” consensus with an average price target of $15.40.

Adherex Technologies (NASDAQ:FENC - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.03, Zacks reports. Adherex Technologies had a negative net margin of 17.12% and a negative return on equity of 43.87%.

Here are the key takeaways from Adherex Technologies' conference call:

• PEDMARK net product sales rose 78% year over year to $17.1 million in Q2 2026, marking the company’s seventh consecutive quarter of growth. Non-GAAP adjusted EBITDA improved to $2.8 million from a $1.2 million loss a year ago.
• Commercial momentum accelerated, with Q2 demand up double digits sequentially, record patient enrollments and infusions, and a 280% increase in sales calls. July produced all-time highs for completed infusions, new enrollments, active patients, and new customers, while the expanded sales force now reaches roughly 5,000 targets.
• Medical and clinical efforts are expanding, including three actively accruing investigator-sponsored studies and an upcoming oral presentation of Japan’s STS-J01 trial data at SIOP 2026. Management said maturing data could support future label expansions and stronger NCCN recommendations, while discussions with potential Japanese and Asia-Pacific partners continue.
• Operating expenses excluding stock-based compensation increased to approximately $13.6 million, driven largely by higher commercial headcount and marketing investments. Management expects cash to decline in Q3 due to customer collection cycles, although it anticipates positive cash generation in Q4 and year-end cash.

Adherex Technologies Price Performance

Adherex Technologies stock traded up $0.82 during mid-day trading on Tuesday, reaching $11.76. The stock had a trading volume of 203,428 shares, compared to its average volume of 203,190. Adherex Technologies has a one year low of $5.65 and a one year high of $13.25. The company has a 50-day moving average price of $10.02 and a two-hundred day moving average price of $8.51. The company has a market capitalization of $412.17 million, a price-to-earnings ratio of -40.57 and a beta of 1.09.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC purchased a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,718 shares of the company's stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 55.51% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on FENC shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Adherex Technologies in a research report on Friday, July 17th. HC Wainwright upped their target price on shares of Adherex Technologies from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, May 22nd. Zacks Research upgraded shares of Adherex Technologies from a "strong sell" rating to a "hold" rating in a research note on Monday, May 25th. Wedbush reiterated an "outperform" rating and issued a $13.00 price target on shares of Adherex Technologies in a research note on Thursday, April 16th. Finally, Wall Street Zen raised shares of Adherex Technologies from a "hold" rating to a "strong-buy" rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Adherex Technologies has an average rating of "Moderate Buy" and an average price target of $15.40.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source